HitGen (SHSE:688222) Cyclically Adjusted Revenue per Share: ¥0.90 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688222 HitGen Inc SHSE:688222
84 GF Score
Price ¥38.64
GF Value ¥26.25
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is HitGen Cyclically Adjusted Revenue per Share?

HitGen SHSE:688222 -3.06% 84 Cyclically Adjusted Revenue per Share is ¥0.90 as of Mar. 2026. GuruFocus rates SHSE:688222 with a GF Score™ of 84/100 and a GF Value™ of ¥26.25 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

HitGen's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was ¥1.296. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥0.90 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-15), HitGen's current stock price is ¥ 38.64. HitGen's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was ¥0.90. HitGen's Cyclically Adjusted PS Ratio of today is 42.93.

During the past 10 years, the highest Cyclically Adjusted PS Ratio of HitGen was 45.71. The lowest was 30.45. And the median was 38.25.


HitGen  (SHSE:688222) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HitGen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=38.64/0.90
=42.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PS Ratio of HitGen was 45.71. The lowest was 30.45. And the median was 38.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


HitGen Cyclically Adjusted Revenue per Share Related Terms


HitGen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for HitGen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HitGen Cyclically Adjusted Revenue per Share Chart

HitGen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.90

HitGen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.90 0.00

SHSE:688222 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, HitGen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HitGen Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HitGen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HitGen's Cyclically Adjusted PS Ratio falls into.


SHSE:688222
84GF Score
HitGen Inc SHSE:688222
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HitGen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HitGen's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.296/115.8323*115.8323
=1.296

Current CPI (Dec. 2025) = 115.8323.

HitGen Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.000 102.600 0.000
201712 0.148 104.500 0.164
201812 0.420 106.500 0.457
201912 0.725 111.200 0.755
202012 0.647 111.500 0.672
202112 0.785 113.108 0.804
202212 0.783 115.116 0.788
202312 0.912 114.781 0.920
202412 1.081 114.893 1.090
202512 1.296 115.832 1.296

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥0.90 mean?
HitGen (SHSE:688222) has a Cyclically Adjusted Revenue per Share of ¥0.90 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on HitGen and its competitors.
Is HitGen's Cyclically Adjusted Revenue per Share too high?
HitGen's current Cyclically Adjusted Revenue per Share is ¥0.90. Overall, HitGen has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HitGen's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
HitGen's Cyclically Adjusted Revenue per Share of ¥0.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on HitGen and its competitors. HitGen's current Cyclically Adjusted Revenue per Share is ¥0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥26.25, compared to a current price of ¥38.64 — trading 47.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥0.90. HitGen's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For HitGen (SHSE:688222), the current Cyclically Adjusted Revenue per Share is ¥0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HitGen (SHSE:688222) Overvalued in 2026?

Based on GuruFocus' analysis, HitGen stock appears to be overvalued. The current stock price of ¥38.64 is trading 47.2% above its estimated GF Value™ of ¥26.25. GuruFocus considers HitGen to be Significantly Overvalued.

Key valuation signals for SHSE:688222:

  • Cyclically Adjusted Revenue per Share: ¥0.90
  • GF Value™: ¥26.25 vs. price of ¥38.64 (47.2% above fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HitGen Business Description

Address Section 2, Biocity Middle Road, Chengdu Tianfu International Biological City, No. 18, Shuangliu District, Sichuan Province, Chengdu, CHN, 610093
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
84GF Score

Get the complete analysis for SHSE:688222

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.64
Price
¥26.25
GF Value